Lung Cancer

Lung Cancer
2024-11-20T06:44:41.993Z

REZILIENT2

REZILIENT2
Lung cancer

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations and other mutations

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Lung Cancer

Study Phase

IIb

Trial Identifiers
GenesisCare Location(s)
North Shore
location pin icon

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

phone icon (02) 8037 4100 email icon admin.northshore@genesiscare.com
NSW
North Shore
Principal Investigator(s)
Medical Oncologist

Prof. Nick Pavlakis

BSc MBBS MMed PhD FRACP

Prof. Nick Pavlakis
location pin icon

Frenchs Forest (Oncology) +1

View Profile
Profile Image - Prof. Nick Pavlakis

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.